Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia

被引:0
作者
Mikkel Krogh-Madsen
Brendan Bender
Morten Krogh Jensen
Ove Juul Nielsen
Lena E. Friberg
Per Hartvig Honoré
机构
[1] University of Copenhagen,Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences
[2] Uppsala University,Department of Pharmaceutical Biosciences, Pharmacometrics Research Group
[3] Herlev Hospital,Department of Haematology L
[4] Rigshospitalet,124
来源
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词
Cytarabine; Etoposide; Daunorubicin; Population pharmacokinetics; NONMEM; Acute myeloid leukemia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1155 / 1163
页数:8
相关论文
共 93 条
[1]  
Estey E(2006)Acute myeloid leukaemia Lancet 368 1894-1907
[2]  
Dohner H(2011)Therapeutic advances in acute myeloid leukemia J Clin Oncol 29 487-494
[3]  
Burnett A(2004)Problems related to resistance to cytarabine in acute myeloid leukemia Leuk Lymphoma 45 1123-1132
[4]  
Wetzler M(1991)Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens Ann Hematol 62 119-128
[5]  
Lowenberg B(1998)Etoposide: four decades of development of a topoisomerase II inhibitor Eur J Cancer 34 1514-1521
[6]  
Cros E(2005)The anthracycline antibiotics: antitumor drugs that alter chromatin structure Bioessays 27 50-56
[7]  
Jordheim L(1997)Anthracyclines in haematology: preclinical studies, toxicity and delivery systems Blood Rev 11 201-223
[8]  
Dumontet C(1993)Pharmacokinetics and metabolism of anthracyclines Cancer Surv 17 219-252
[9]  
Galmarini CM(2011)Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia Br J Clin Pharmacol 71 514-521
[10]  
Hiddemann W(1995)Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study Cancer Chemother Pharmacol 36 425-430